Article
Pharmacology & Pharmacy
Fang Wang, Xiaofei Li, Yanting Shi, He Zhou, Gang Yang, Ruixia Li, Tong Wu, Jie Liang
Summary: This study found that the ADA biosimilar HS016 had good efficacy and safety in Chinese IBD patients. The majority of Crohn's disease and ulcerative colitis patients achieved clinical response and remission after treatment with HS016.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Gastroenterology & Hepatology
Parakkal Deepak, Quazim A. Alayo, Aava Khatiwada, Bixuan Lin, Marc Fenster, Christina Dimopoulos, Geoffrey Bader, Roni Weisshof, Michael Jacobs, Alexandra Gutierrez, Matthew A. Ciorba, George P. Christophi, Anish Patel, Robert P. Hirten, Jean-Frederic Colombel, David T. Rubin, Christina Ha, Poonam Beniwal-Patel, Ryan C. Ungaro, Gaurav Syal, Joel Pekow, Benjamin L. Cohen, Andres Yarur
Summary: In a real-world study of UC patients given tofacitinib, adverse events occurred in 15.7% of patients, most of which were infections. Serious adverse events occurred at a rate of 10.0%, with HZ infection and VTE primarily occurring in patients receiving 10 mg tofacitinib twice per day.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Pepijn W. A. Thomas, Nathan den Broeder, Monique Derikx, Wietske Kievit, Rachel L. West, Maurice G. V. M. Russel, Jeroen M. Jansen, Tessa E. H. Romkens, Frank Hoentjen
Summary: Initiating biological therapy or tofacitinib can reduce work impairment in patients with IBD. Patients who achieve clinical remission or response show the greatest improvement, especially those with ulcerative colitis and IBD-unclassified.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Gastroenterology & Hepatology
Ligia Yukie Sassaki, Sender J. Miszputen, Roberto Luiz Kaiser Junior, Wilson R. Catapani, Mauro Bafutto, Antonio S. Scotton, Cyrla Zaltman, Julio Pinheiro Baima, Hagata S. Ramos, Mikaell Alexandre Gouvea Faria, Carolina D. Goncalves, Isabella Miranda Guimaraes, Cristina Flores, Heda M. B. S. Amarante, Rodrigo Bremer Nones, Jose Miguel Luz Parente, Murilo Moura Lima, Julio Maria Chebli, Maria de Lourdes Abreu Ferrari, Julia F. Campos, Maria G. P. Sanna, Odery Ramos, Rogerio Serafim Parra, Jose J. R. da Rocha, Omar Feres, Marley R. Feitosa, Rosana Fusaro Caratin, Juliana Senra, Genoile Oliveira Santana
Summary: The RISE BR study aimed to evaluate disease control, treatment patterns, and disease burden among patients with moderate-to-severe active inflammatory bowel disease in Brazil. Findings from the prospective follow-up phase showed that a significant proportion of patients achieved disease control, but it took considerable time to achieve this outcome in a real-world Brazilian setting.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Medicine, Research & Experimental
Ran Jin, Chidozie Nduka, Delphine Courmier, Hannah Knight, Rachael Meadows, James Piercy, J. R. F. Cummings, Waldemar Radziszewski
Summary: The use of ABP 501 biosimilar in the treatment of inflammatory bowel disease has shown positive outcomes and high satisfaction among patients.
ADVANCES IN THERAPY
(2023)
Article
Gastroenterology & Hepatology
Mikihiro Fujiya, Tsutomu Kawaguchi, Shoko Arai, Naoki Isogawa, Shintaro Hiro, Fumihiro Matsumoto, Satoshi Yamaguchi, Noritoshi Yoshii, Mashio Nakamura, Katsuyoshi Matsuoka
Summary: This study provides insight into the incidence and risk factors for VTE in patients with IBD from Japan.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Review
Immunology
Yuanzhuo Wang, Ziqi Wan, Rui Jin, Tianming Xu, Yan Ouyang, Baihui Wang, Gechong Ruan, Xiaoyin Bai
Summary: Extraintestinal manifestations (EIMs) are common in patients with inflammatory bowel disease (IBD) and managing these manifestations is difficult. Recent research has found that tofacitinib (TOF) may be a promising option for treating EIMs. TOF may benefit EIMs in ulcerative colitis, and higher doses and longer treatment times may increase its effectiveness. However, more specific research and large prospective studies are needed.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Chemistry, Medicinal
Vlasta Orsic Fric, Vladimir Borzan, Ines Sahinovic, Andrej Borzan, Sven Kurbel
Summary: This study compared the clinical outcomes of intravenous and subcutaneous vedolizumab in inflammatory bowel disease patients. They found that subcutaneous administration resulted in higher drug concentration and demonstrated comparable efficacy and safety to intravenous administration. Few patients discontinued therapy due to loss of response, and the most common adverse event was COVID-19.
Review
Cardiac & Cardiovascular Systems
A. S. Giordani, A. Candelora, M. Fiacca, C. Cheng, B. Barberio, A. Baritussio, R. Marcolongo, S. Iliceto, E. Carturan, M. De Gaspari, S. Rizzo, C. Basso, G. Tarantini, E. V. Savarino, A. L. P. Caforio
Summary: This study retrospectively analyzed data and conducted a literature review on myocarditis associated with inflammatory bowel diseases (IBD). It found that myocarditis in association with IBD is more common in young males and generally has a benign clinical course, but a subset of patients may develop giant cell myocarditis and require immunosuppression.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2023)
Article
Gastroenterology & Hepatology
Ariela K. Holmer, Jiyu Luo, Kirk B. Russ, Sarah Park, Jeong Yun Yang, Furkan Ertem, Jeffrey Dueker, Vu Nguyen, Simon Hong, Cameron Zenger, Jordan E. Axelrad, Anthony Sofia, Jessica C. Petrov, Badr Al-Bawardy, David I. Fudman, Ernesto Llano, Joseph Dailey, Sushrut Jangi, Nidah Khakoo, Oriana M. Damas, Edward L. Barnes, Frank I. Scott, Ryan C. Ungaro, Siddharth Singh
Summary: A retrospective cohort study compared the safety of TNF-a antagonists and non-TNF biologics in patients with IBD and active or recent cancer. The results showed similar risks of cancer progression and recurrence between the two treatment groups. Therefore, the choice of biologic should be based on IBD disease severity in collaboration with an oncologist.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Review
Rheumatology
Rachel Knevel, Katherine P. Liao
Summary: With the global digitalization of medical records, electronic health records (EHRs) have become an increasingly important source of real-world data (RWD). EHR data contain a broad collection of healthcare data covering the multitude of real-life patients and the healthcare processes related to their care. Machine learning (ML) is a powerful method that allows us to leverage a large amount of heterogeneous clinical data for clinical algorithms, but requires extensive training, testing, and validation.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Gastroenterology & Hepatology
Ahmed B. Bayoumy, Jasmijn Z. Jagt, Herbert M. van Wering, Lissy de Ridder, Thalia Hummel, Victorien M. Wolters, Janneke Stapelbroek, Marc A. Benninga, Chris J. J. Mulder, Nanne K. H. de Boer, Tim G. J. de Meij
Summary: This study evaluated the safety of thioguanine (TG) as maintenance therapy for pediatric inflammatory bowel disease (IBD). The results showed that TG is a safe alternative for patients with AZA-induced pancreatitis.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
(2022)
Article
Immunology
Desiree Tampe, Philipp Stroebel, Peter Korsten, Samy Hakroush, Bjoern Tampe
Summary: This study aimed to identify the determinants for considering therapeutic plasma exchange in patients with severe AAV requiring intensive care treatment. The decision to consider plasma exchange was more likely in patients with severe renal dysfunction and need for intensive care treatment. However, short-term outcomes did not depend on clinical or laboratory characteristics at admission, with only increased global glomerular sclerosis in renal biopsies associated with a detrimental short-term outcome. Further investigation is needed in a prospective controlled setting to guide therapeutic decision making for patients with severe AAV requiring intensive care treatment.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, Research & Experimental
Brian Bressler, Jennifer Jones, Tracy S. H. In, Tommy Lan, Cristian Iconaru, John K. Marshall
Summary: This study estimated the long-term persistence of ustekinumab in patients with inflammatory bowel disease. The results showed that over three-fourths of patients continued using ustekinumab after 1 year, and more than half of Crohn's disease patients continued usage after 4 years. Further analysis indicated that patients who had never received biologic therapy before were more likely to continue treatment with ustekinumab.
ADVANCES IN THERAPY
(2023)
Review
Gastroenterology & Hepatology
Carlos Taxonera, David Olivares, Cristina Alba
Summary: This study confirms the effectiveness of tofacitinib in promoting clinical remission and corticosteroid-free remission in patients with moderate to severely active UC. It also found that tofacitinib has made progress in mucosal healing in UC treatment. Additionally, the safety profile of tofacitinib in UC treatment was found to be acceptable.
INFLAMMATORY BOWEL DISEASES
(2022)
